Mexico seeks to enter the beginning of the phase 3 study that the biotecnología Novavax Inc has started to evaluate the efficacy of its NVX-CoV2373 vaccine.
This trial may begin once the Federal Commission for the Protection against Sanitary Risks (Cofepris) grant your approval.
The Ministry of Foreign Relations (SRE) announced this morning that Novavax has already announced the start of its phase III study in Mexico and the United States, the purpose of which is to evaluate the efficacy of the NVX-CoV2373 vaccine against the COVID-19 disease .
It seeks to recruit, in Mexico, 2,000 volunteers in seven regions throughout the Republic, to collect data on the efficacy of the vaccine in the Mexican population. This Novavax research will have up to 30 thousand volunteers, of legal age, in 115 different sites, globally.
“Previous clinical trials showed that the vaccine elicited a strong immune response against the virus and it was well tolerated. The new Novavax study plans to recruit volunteers who belong to the demographic groups that have been most affected by the SARS-CoV-2 virus, as well as older adults or those with comorbidities ”, detailed Foreign Relations.
The vacuna NVX-CoV2373 it has been developed with support from the United States Government.